ADINA Act
Take action
Record your position on this measure.
Create an account to take a stance, submit a written position, or contact your legislator.
Progress
Where this bill stands in the legislative process.
- Introduced
- Passed House
- Passed Senate
- To President
- Became Law
Overview
This bill, the Allergen Disclosure In Non-food Articles Act (ADINA Act), aims to improve patient safety by requiring drug labels to clearly identify any ingredients that are major food allergens or derived from gluten-containing grains. Currently, drug labels may not always disclose these potential allergens, which can cause serious reactions in sensitive individuals. The bill mandates that drug labels include a specific statement and a list of these ingredients, ensuring consumers are fully informed before taking medication.
Key provisions
- Requires drug labels to identify ingredients that are major food allergens.
- Requires drug labels to identify ingredients derived from gluten-containing grains (wheat, barley, rye).
- Addresses misbranding of drugs that fail to disclose these ingredients.
- The disclosure requirements apply to drugs intended for human use.
Who is affected
- Patients taking medications
- Pharmaceutical manufacturers
- The Food and Drug Administration (FDA)
Notable changes
- Adds a new provision to the Federal Food, Drug, and Cosmetic Act regarding allergen labeling.
- Establishes a timeline for implementation, starting two years after the bill's enactment.
Bill text
Read the latest version inline or switch to a previous version.
Text extraction is in progress. View the official source.
Sponsors
Official sponsors from legislative records.
22 on record
Primary sponsor
Cosponsors
Arguments
Reasons offered for and against this legislation.
Arguments in favor
No arguments in favor have been submitted.
Submit yoursArguments opposed
No arguments opposed have been submitted.
Submit yours